Outcomes with two different schedules of bortezomib, melphalan, and prednisone (VMP) for previously untreated multiple myeloma: matched pair analysis using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials

1. Mateos, M.-V.
2. Oriol, A.
3. Martínez-López, J.
4. Teruel, A.-I.
5. Bengoechea, E.
6. Palomera, L.
7. de Arriba, F.
8. Esseltine, D.-L.
9. Cakana, A.
10. Pei, L.
11. van de Velde, H.
12. Miguel, J.S.